Novo Nordisk A/s

Ulrich Sensfuss

Jesper F Lau

Palle Jakobsen

Thomas Kruse

Henning Thoegersen

Peter Kresten Nielsen

Thomas Kruse Hansen

Kjeld Madsen

Michael Ankersen

Thomas Hoeg-Jensen

Leif Hoejslet Christensen

Nils Langeland Johansen

Jane Spetzler

Steffen Reedtz-Runge

Birgitte Schjellerup Wulff

Ulla Ribel-Madsen

Kilian Waldemar Conde Frieboes

Christian Fledelius

Christian Wenzel Tornoee

Ingrid Petterson

Kilian Waldemar Conde-Frieboes

Henning THØGERSEN

Christian Wenzel TORNØE

The present invention relates to novel glucagon derivatives which are GLP-1/glucagon receptor co-agonists, and to the use of the glucagon derivatives in medicine, such as in the treatment of diabetes, obesity and related diseases and conditions.

GLP-1/glucagon receptor co-agonists for medical use

New GLP-1 derivatives, compositions thereof and their use in medicine.

Stable GLP-1 based GLP-1/glucagon receptor co-agonists

The invention relates to novel stable and protracted GLP-1/glucagon receptor co-agonists, to the use of said peptides in therapy, to methods of treatment comprising administration of said peptides to patients, and to the use of said peptides in the manufacture of medicaments.

Stable, protracted GLP-1/glucagon receptor co-agonists for medical use

The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.

Glucagon analogues

Novel cyclic and linear peptides of the formula R&#x2014;X&#x2014;X&#x2014;X&#x2014;X&#x2014;X&#x2014;X&#x2014;X&#x2014;X&#x2014;X&#x2014;X&#x2014;X&#x2014;X&#x2014;Rare useful in the treatment of obesity are provided.

Peptides for use in treating obesity

Small cyclic peptides of the formula X1-X2-X3-X4-X5-X6-X7-Rcomprising 7-12 amino acid residues are provided. Said peptides are MC4 receptor agonists, and thus useful in the treatment of obesity and related diseases.

Melanocortin receptor agonists

Growing community of inventors

Vanloese, Denmark

Ulrich Sensfuss